The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
In what seems a significant step forward in pain management, the US Food and Drug Administration has approved a new non-opioid painkiller for treating short-term pain in adults. Veuer’s Maria Mercedes ...
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioi ...
The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback